# JS001sc or JS001 Plus Chemotherapy is Indicated for Relapsed or Metastatic First-Line Non-Squamous Non Small Cell Lung Cancer（NSCLC）

Source: https://onco.cc/trials/nct06505837/  
OnCo record `nct06505837` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of pemetrexed and toripalimab in lung cancer, run by Shanghai Junshi Bioscience Co., Ltd., active but no longer recruiting.

## Summary

JS001sc or JS001 Plus Chemotherapy is Indicated for Relapsed or Metastatic First-Line Non-Squamous Non Small Cell Lung Cancer（NSCLC） is a phase 3, randomised interventional study registered as NCT06505837 by Shanghai Junshi Bioscience Co., Ltd., with a registry enrolment figure of 395 participants, started 2024-07-11 and due to reach its primary completion in 2026-06-30. Interventions recorded: JS001sc (360mg Subcutaneous injection) and pemetrexed/platinum-containing chemotherapy; JS001 (240mg intravenous infusion) and pemetrexed/platinum-containing chemotherapy. Conditions listed: Recurrent Metastatic Non-Squamous Non Small Cell Lung Cancer. Primary outcome: Observed serum Ctrough at Cycle 1; Model-predicted area under the concentration-time curve(AUC) from 0 to 21 days at Cycle 1. Lung eligibility wording from the registry: "Histologically or cytologically confirmed relapsed or metastatic non-squamous NSCLC". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT06505837
- Phase: 3
- Setting: Open-Label, Randomized, Phase III Clinical Study Comparing the Pharmacokinetic Profile, Efficacy, and Safety of JS001sc and JS001 in Combination With Standard Chemotherapy as First-Line Treatment for Recurrent Metastatic Non-Squamous Non Small Cell Lung Cancer
- Sponsor: Shanghai Junshi Bioscience Co., Ltd.
- Enrolled: 395

## Sources

- ClinicalTrials.gov NCT06505837: https://clinicaltrials.gov/study/NCT06505837

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Pemetrexed](https://onco.cc/drugs/pemetrexed/), [Toripalimab](https://onco.cc/drugs/toripalimab/)
- companies: [Shanghai Junshi Biosciences](https://onco.cc/companies/junshi/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06505837.json